Skip to main content
Roivant Sciences Ltd. logo

Roivant Sciences Ltd. — Investor Relations & Filings

Ticker · ROIV ISIN · BMG762791017 LEI · 549300DL466NY5J6U724 US Manufacturing
Open in API
Filings indexed 862 across all filing types
Latest filing 2022-02-01 Major Shareholding Noti…
Country BM Bermuda
Listing US ROIV

About Roivant Sciences Ltd.

http://roivant.com/

Roivant Sciences is a biopharmaceutical company that develops and commercializes medicines and technologies. The company operates a unique model by building agile, focused subsidiary companies known as 'Vants' to advance specific assets. This structure is designed to accelerate the discovery, development, and delivery of innovative treatments to patients through efficient capital allocation and execution. Roivant employs technology, including artificial intelligence for drug discovery and protein design, across its operations. The company's portfolio spans multiple therapeutic areas, such as autoimmune and pulmonary diseases, and includes commercial-stage products like Vtama for psoriasis and atopic dermatitis, alongside a broad pipeline of investigational drugs.

Recent filings

Filing Released Lang Actions
SC 13G
Major Shareholding Notification
2022-02-01 English
Regulatory Filings 2022
Regulatory Filings
2022-01-05 English
424B3
Capital/Financing Update Classification · 95% confidence The document is a prospectus filed pursuant to Rule 424(b)(3) related to the registration and potential sale of common shares by securityholders. It includes detailed information about the offering, the business combination, risk factors, management discussion and analysis, executive compensation, principal securityholders, and other related disclosures. The presence of terms like 'prospectus', 'registration statement', 'Rule 424(b)(3)', and detailed offering information indicates this is a capital markets filing related to securities offering. This type of document is best classified as a Capital/Financing Update (CAP), as it pertains to the registration and sale of shares and related financing activities rather than an annual report, earnings release, or other categories.
2022-01-04 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a letter from Roivant Sciences Ltd. to the SEC requesting acceleration of effectiveness of a registration statement on Form S-1. It references Rule 461 under the Securities Act of 1933 and is related to the registration process for securities offerings. The document is short (1318 characters) and is a correspondence related to a regulatory filing, not the filing itself. It does not contain financial statements or detailed report content. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and correspondence that do not fit other categories.
2021-12-30 English
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. There is no indication of the document being a report itself or an announcement. Given the lack of discernible information and the fallback rule for documents that do not fit any specific category, the appropriate classification is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but without meaningful content, it cannot be classified as a financial or corporate report.
2021-12-29 English
S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for registering securities for public offering under the Securities Act of 1933. It includes detailed information about the securities being registered, the offering, risk factors, use of proceeds, management discussion, and other disclosures typical of a registration statement prospectus. This is not an annual report, earnings release, or any other financial report type. It is a capital markets filing related to the registration of securities for sale to the public. According to the filing definitions, updates on company fundraising or financing activities, including registration statements for securities offerings, fall under Capital/Financing Update (CAP). Therefore, the correct classification is CAP with high confidence.
2021-12-22 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.